ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project

Blood

Volumn 111, Issue 12, 2008, Pages 5496-5504

  Savage, Kerry J ^a   Harris, Nancy Lee ^b   Vose, Julie M ^c   Ullrich, Fred ^c   Jaffe, Elaine S ^d   Connors, Joseph M ^a   Rimsza, Lisa ^e   Pileri, Stefano A ^f   Chhanabhai, Mukesh ^a   Gascoyne, Randy D ^a   Armitage, James O ^c   Weisenburger, Dennis D ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ADULT; ALK+ ANAPLASTIC LARGE CELL LYMPHOMA; ALK- ANAPLASTIC LARGE CELL LYMPHOMA; ARTICLE; CANCER CLASSIFICATION; CANCER RELAPSE; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA NOT OTHERWISE SPECIFIED; PRIORITY JOURNAL; PROGNOSIS; SKIN LYMPHOMA; SURVIVAL RATE; SURVIVAL TIME; ANAPLASTIC LARGE CELL LYMPHOMA; ASIA; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; EUROPE; FOLLOW UP; IMMUNOLOGY; INTERNATIONAL COOPERATION; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NORTH AMERICA; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SKIN TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; ASIA; DIAGNOSIS, DIFFERENTIAL; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; INTERNATIONAL COOPERATION; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NORTH AMERICA; PROGNOSIS; PROTEIN-TYROSINE KINASES; RECURRENCE; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 47049084821     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-134270     Document Type: Article

References (25)

1. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
2. Jaffe ES, Harris NL, Stein H, Vardiman J. World Health Organization Classification: Tumours of Hematopoetic and Lymphoid Tissues. Lyon. France: IARC Press; 2001.
3. Mason DY Bastard C, Rimokh R, et al. CD30-positive large cell lymphomas ("Ki-1 lymphoma'') are associated with a chromosomal translocation involving 5q35. Br J Haematol. 1990;74:161-168.
4. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma [letter]. Science. 1995;267:316-317.
5. Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol. 2002;20:3691-3702.
6. Weisenburger DD, Anderson JR, Diebold J, et al. Systemic anaplastic large-cell lymphoma: results from the Non-Hodgkin's Lymphoma Classification Project. Am J Hematol. 2001;67:172-178.
7. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol. 1998;153:875-886.
8. Falini B, Pileri S, Zinzani PL, et al.ALK + lymphoma: clinico-pathological findings and outcome. Blood. 1999;93:2697-2706.
9. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913-3921.
10. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 2000;53:445-450.
11. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001;114:741-760.
12. Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109:2156-2164.
13. Zettl A, RudigerT, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol. 2004;164:1837-1848.
14. Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK- negative anaplastic large cell lymphomas. Br J Haematol. 2008;140:516-526.
15. Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol. 2007;127:707-722.
16. ten Berge RL, de Bruin PC, Oudejans JJ, Ossen-koppele GJ, van der Valk P, Meijer CJ. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology. 2003;43:462-469.
17. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects: a review. J Pathol. 2003;200:4-15.
18. Shipp M, Harrington D, Chairpersons Anderson J, et al. A predictive model for aggressive non-Hodgkin's lymphoma: the International NHL Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
19. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474-2479.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
22. Shiota M. Nakamura S. Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995;86:1954-1960.
23. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-1514.
24. Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104:3358-3360.
25. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653-3661.